Ablative Therapies for Localized Primary Renal Cell Carcinoma
Surgery with either partial or radical nephrectomy remains the standard of care for localized primary renal cell carcinoma (RCC). However, most RCCs are detected in an older age group, and some may have multiple comorbidities that preclude surgery. Thermal ablation (TA) with radiofrequency ablation...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Société Internationale d’Urologie Journal |
| Subjects: | |
| Online Access: | https://siuj.org/index.php/siuj/article/download/227/172 |
| _version_ | 1797226223521234944 |
|---|---|
| author | Muhammad Ali Vanessa Acosta Ruiz Sarah P. Psutka David Liu Shankar Siva |
| author_facet | Muhammad Ali Vanessa Acosta Ruiz Sarah P. Psutka David Liu Shankar Siva |
| author_sort | Muhammad Ali |
| collection | DOAJ |
| description | Surgery with either partial or radical nephrectomy remains the standard of care for localized primary renal cell carcinoma (RCC). However, most RCCs are detected in an older age group, and some may have multiple comorbidities that preclude surgery. Thermal ablation (TA) with radiofrequency ablation (RFA), cryoablation (CA), or microwave ablation (MWA) is considered an alternative to extirpative surgical procedures for select patients with small renal tumors. There is more than 90% post-ablation local control in carefully selected patients with reported complication rates of less than 10%. Most thermal ablation require only a single procedure. More recently, stereotactic ablative body radiotherapy (SABR) has emerged as an attractive noninvasive treatment modality for elderly patients with comorbidities and localized RCC. It has shown more than 90% local control rates for both small and relatively larger tumors (> 4 cm). Modest post-SABR renal function decline has been observed. Despite most patients presenting with mild or moderate chronic kidney disease there is less than a 5% chance of progression to end-stage renal disease. This article aims to summarize the key evidence and ablative treatment’s optimal patient selection, efficacy, and toxicity. |
| first_indexed | 2024-03-11T20:06:28Z |
| format | Article |
| id | doaj.art-6a3e8201481e4091a48f6c0f7748928e |
| institution | Directory Open Access Journal |
| issn | 2563-6499 |
| language | English |
| last_indexed | 2024-04-24T14:21:30Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Société Internationale d’Urologie Journal |
| spelling | doaj.art-6a3e8201481e4091a48f6c0f7748928e2024-04-03T06:41:19ZengMDPI AGSociété Internationale d’Urologie Journal2563-64992022-11-013643744910.48083/UEML5802Ablative Therapies for Localized Primary Renal Cell CarcinomaMuhammad AliVanessa Acosta RuizSarah P. PsutkaDavid LiuShankar SivaSurgery with either partial or radical nephrectomy remains the standard of care for localized primary renal cell carcinoma (RCC). However, most RCCs are detected in an older age group, and some may have multiple comorbidities that preclude surgery. Thermal ablation (TA) with radiofrequency ablation (RFA), cryoablation (CA), or microwave ablation (MWA) is considered an alternative to extirpative surgical procedures for select patients with small renal tumors. There is more than 90% post-ablation local control in carefully selected patients with reported complication rates of less than 10%. Most thermal ablation require only a single procedure. More recently, stereotactic ablative body radiotherapy (SABR) has emerged as an attractive noninvasive treatment modality for elderly patients with comorbidities and localized RCC. It has shown more than 90% local control rates for both small and relatively larger tumors (> 4 cm). Modest post-SABR renal function decline has been observed. Despite most patients presenting with mild or moderate chronic kidney disease there is less than a 5% chance of progression to end-stage renal disease. This article aims to summarize the key evidence and ablative treatment’s optimal patient selection, efficacy, and toxicity.https://siuj.org/index.php/siuj/article/download/227/172renal cell carcinomastereotactic ablative radiotherapythermal ablationmicrowave ablationsabrradiofrequency ablationrfa |
| spellingShingle | Muhammad Ali Vanessa Acosta Ruiz Sarah P. Psutka David Liu Shankar Siva Ablative Therapies for Localized Primary Renal Cell Carcinoma Société Internationale d’Urologie Journal renal cell carcinoma stereotactic ablative radiotherapy thermal ablation microwave ablation sabr radiofrequency ablation rfa |
| title | Ablative Therapies for Localized Primary Renal Cell Carcinoma |
| title_full | Ablative Therapies for Localized Primary Renal Cell Carcinoma |
| title_fullStr | Ablative Therapies for Localized Primary Renal Cell Carcinoma |
| title_full_unstemmed | Ablative Therapies for Localized Primary Renal Cell Carcinoma |
| title_short | Ablative Therapies for Localized Primary Renal Cell Carcinoma |
| title_sort | ablative therapies for localized primary renal cell carcinoma |
| topic | renal cell carcinoma stereotactic ablative radiotherapy thermal ablation microwave ablation sabr radiofrequency ablation rfa |
| url | https://siuj.org/index.php/siuj/article/download/227/172 |
| work_keys_str_mv | AT muhammadali ablativetherapiesforlocalizedprimaryrenalcellcarcinoma AT vanessaacostaruiz ablativetherapiesforlocalizedprimaryrenalcellcarcinoma AT sarahppsutka ablativetherapiesforlocalizedprimaryrenalcellcarcinoma AT davidliu ablativetherapiesforlocalizedprimaryrenalcellcarcinoma AT shankarsiva ablativetherapiesforlocalizedprimaryrenalcellcarcinoma |